All Blog Posts (1,674)

Early Diagnosis: A Paradigm Shift in How we Think About and Approach Cancers

Contributing Editors: Amit Kumar, Ph.D and Robert Berman

For nearly 45 years, the national dialogue, when it comes to cancers, has remained essentially the same. We have been racing for the cure, praying for the cure, searching for the cure, researching for the cure, raising money for the cure, funding the cure, and developing treatments for the cure. Curing cancer has become the “national cancer objective”.…

Continue

Added by Editorial Team on March 11, 2016 at 9:30am — No Comments

Industry Visionaries Meet to Explore New Combination Cancer Drug Development Paradigm

Senior leaders from more than a dozen biopharmaceutical companies came together today with world-class academic clinicians from four leading cancer centers, representatives from oncology non-profits, the FDA, and other key stakeholder organizations to advance the most promising avenues for curing cancer: accelerating the development of investigational drug combination therapies of two or more investigational treatments which may hold great promise for cancer patients. 

The endeavor,…

Continue

Added by Editorial Team on March 7, 2016 at 2:00pm — No Comments

ASCO GI: Establishing Abraxane® + gemcitabine as the Foundation for Research in First-line Metastatic Pancreatic Cancer

Located just behind the stomach, measuring about 6 inches long and less than 2 inches wide, is an organ called the pancreas. Shaped like a fish with a wide head, a tapering body and a small, pointed tail, the pancreas contains 2 different types of glands - exocrine and endocrine - which are a vital part of the digestive system and a critical controller of blood sugar levels.

Tumors of the pancreas are malignant neoplasms arising in the pancreas. Because of its 'hidden' location, these…

Continue

Added by Editorial Team on February 1, 2016 at 10:00pm — No Comments

Oasmia Confirms Data Suggesting Equal Efficacy for Novel Therapeutic Paclical® and US-Approved Abraxane®

By Sonia Portillo, Medical Writer

In the current oncology therapeutics market, an estimated $45 billion is brought in through cytogenic therapeutics. Of that amount, 70% is attributed to generic cytostatics, which are largely dominated by paclitaxel-based products Taxol and Abraxane® (Celgene). In fact, before going generic, Taxol brought in around 1.6 billion dollars annually, and it was used for 16 cancer indexes. Just last…

Continue

Added by Editorial Team on January 22, 2016 at 8:30pm — No Comments

Asbestos: Still A Threat Today

Although the United States has curtailed the use of asbestos-containing products in residential and commercial construction, the effects of asbestos exposure are still a major concern. Additionally, there are several places around the world where asbestos exposure is still quite high. Asbestos occurs naturally in the ground in countries like Turkey.…

Continue

Added by Editorial Team on December 18, 2015 at 9:00am — No Comments

Changes in Cervical Cancer Stage at Diagnosis and Initial Treatment Among Young Women Before and After ACA

Although based on early data, study findings suggest an association between the Affordable Care Act Dependent Coverage Expansion provision and cervical cancer stage at diagnosis and receipt of fertility-sparing treatment among young women age 21 to 25 years, but not among women aged 26 to 34 years, according to a study, supported by the Intramural Research Department of the American Cancer Society, published in the November 24 issue of JAMA.

In September 2010,…

Continue

Added by Editorial Team on November 24, 2015 at 10:30am — No Comments

New Engineered Material May Advance Bone-grafting Treatments For Cancer Patients

Biomedical engineers at Texas A&M University, committed to solving the world’s greatest health problems through the exploration of new ideas, integrated research and innovation, have developed a new technology focusing on a new synthetic material that’s strong enough to fill gaps in bone while stimulating new bone growth that could advance the grafting treatments needed by people suffering from bone cancer and other bone defects.

"This material serves as a biodegradable scaffold…

Continue

Added by Editorial Team on November 19, 2015 at 9:00am — No Comments

Oncolytic Virotherapy Enters Early Phase Clinical Trials

Ludwig Cancer Research, an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for more than 40 years, and the Cancer Research Institute (CRI), the world's only non-profit organization dedicated exclusively to transforming cancer patient care by advancing scientific efforts to develop new and effective immune system-based strategies to prevent, diagnose, treat, and…

Continue

Added by Editorial Team on November 18, 2015 at 4:00pm — No Comments

Dana-Farber, Brigham and Women's, Boston's Children's Hospital and Broad Institute to Collaborate to Harness Genetic Data for Patients

The Joint Center for Cancer Precision Medicine, a collaborative initiative to create “precision medicine treatment pathways” for patients with advanced cancers and to speed the development of personalized therapies has been established as part of a collaboration between the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, and the Broad Institute of MIT and Harvard. 

The new Joint Center brings together expertise and resources in state-of-the-art…

Continue

Added by Editorial Team on November 17, 2015 at 3:00pm — No Comments

America's National Physicians Organization Calls to End Direct to Consumer Advertising of Prescription Drugs

Marketing of prescription medications and medical devices directly to consumers has, for many years, been the focus of considerable - ongoing - debate. Proponents argue that Direct-to-Consumer or DTC advertisingis an important tool to informs consumers - as well as patients - about important, treatable health conditions. It encourages and…

Continue

Added by Editorial Team on November 17, 2015 at 9:00am — No Comments

U.S. FDA Approves Osimertinib for the Treatment of Patients with Metastatic EGFR T790M Mutation-positive Non-small Cell Lung Cancer

Lung cancer is the leading cause of cancer death among both men and women, accounting for about one-third of all cancer deaths, more than breast, prostate and colorectal cancers combined. Lung cancer has a five-year survival rate that is less than 20%. Approximately 85% of all lung cancers in the U.S. are Non-small Cell Lung Cancers (NSCLC). Approximately 10% to 15% of these are EGFR mutation-positive.

Over the past decade, small-molecule EGFR tyrosine kinase…

Continue

Added by Editorial Team on November 16, 2015 at 11:30am — No Comments

First Patient Dosed in Oryzon Genomics' Phase I Extension Cohort of ORY-1001 in Patients with Acute Myeloid Leukemia

Earlier today Oryzon Genomics, a clinical stage biopharmaceutical company based in Barcelona (Spain) leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced the dosing of the first patient in the extension cohort (Part 2) of its ORY-1001 Phase I clinical trial. The trial will take place in 10 centers in Spain, UK and France.

ORY-1001 is a highly selective and potent LSD1 inhibitor which is…

Continue

Added by Editorial Team on November 10, 2015 at 4:00pm — No Comments

The Critical Role Physicians Play in Ensuring Bladder Cancer Patients Understand the Link between Smoking and Their Disease

When bladder cancer patients are well-informed by their physicians, they acknowledge that tobacco use was likely the cause of their disease. The finding comes from a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. Patients with such knowledge may be more motivated to quit smoking, which could help prolong their lives.

According the American Cancer Society, in the United States about 74,000 new cases of bladder…

Continue

Added by Peter Hofland, PhD on November 10, 2015 at 10:00am — No Comments

Epacadostat in Combination with Pembrolizumab Demonstrates 53% Overall Response Rate across a Number of Cancer Types

Results from a phase I/II dose-escalation and dose-expansion study of epacadostat (incb024360; Incyte Corporation)*, a potent, selective inhibitor of indoleamine 2,3-dioxygenase 1 (also known as IDO1), in combination with pembrolizumab (Keytruda®; formerly known as MK-3475 and lambrolizumab; Merck & Co., Inc) were reported earlier today during the 30th Anniversary Annual Meeting Late-Breaking…

Continue

Added by Editorial Team on November 6, 2015 at 5:30pm — No Comments

Study Shows Encouraging Data in Patients with Synovial Sarcoma Receiving NY-ESO Affinity Enhanced T-Cell Therapy

Synovial sarcomas are rare and aggressive soft tissue sarcomas developing in connective tissues, general near joints. The condition may, in the early stages of the disease, not cause noticeable signs or symptoms. Frequently spreading from their original location, synovial sarcomas are often difficult to treat with standard therapies.

One potentially new treatment involves genetically modifying immune cells which are designed to recognize and attack cancer cells. Giving these…

Continue

Added by Editorial Team on November 5, 2015 at 1:30pm — No Comments

Proof of Principle: First Precision Medicine Trial in Cancer Prevention Identifies Molecular-based Chemoprevention Strategy

A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.

The findings, published in the November 5, 2015 online issue of Journal of the…

Continue

Added by Editorial Team on November 5, 2015 at 11:00am — No Comments

Ten (10) Tell-Tale Signs Your Aging Parent Can’t Live Alone

By Carolyn Brent, MBA, Contributing Author

It’s a sad reality that, as we age, we become less independent than we once were – but for most blessed with longevity, it’s inevitable. With an estimated 13 million baby boomers throughout the U.S. caring for elderly parents, throngs of adult caregivers struggle with determining if their parent is fit to remain living…

Continue

Added by Editorial Team on November 4, 2015 at 7:30pm — No Comments

FDA Approves First Oncolytic Viral Therapy for the Treatment Patients with Unresectable Cutaneous, Subcutaneous and Nodal Lesions in Melanoma Recurrent After Initial Surgery

The concept of viruses to treat human malignancy is not new. In the mid 1890's William B. Coley, a New York surgeon, noted that infections could result in an impressive tumor response.[1] Not much later, Louis Pasteur observed that patients with cervical cancer showed regression after being vaccinated with an attenuated rabies virus. By the mid-twentieth century scientists understood that some viruses were able to invade almost any cell in the body and kill it. However, it would not…

Continue

Added by Editorial Team on October 28, 2015 at 6:30pm — No Comments

Who is Really Winning the War on Cancer? - A Look at the Profitability of Cancer Care in America

By John Leifer - Contributing editor

Providers of cancer treatment and therapeutics have learned to carefully hone their rhetoric so that it conveys a socially appropriate sense of altruism. Yet, beneath this thin veneer exists a motivation every bit as powerful as saving lives – reaping billions of dollars in profit. That’s what’s at stake in the…

Continue

Added by Editorial Team on October 16, 2015 at 10:30am — No Comments

Companies Expand Clinical Collaboration to Include Phase III Study Investigating the Combination of Epacadostat with Pembrolizumab as First-line Treatment for Advanced Melanoma

Earlier today Incyte Corporation and Merck & Co., Inc , known as MSD outside the United States and Canada, announced that they have agreed to expand the ongoing clinical trial collaboration to include a Phase III study evaluating the combination of epacadostat, Incyte’s investigational selective Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, with pembrolizumab (Keytruda®)*, Merck’s anti-PD-1 therapy, as first-line treatment for patients with advanced or metastatic melanoma.

The…

Continue

Added by Editorial Team on October 13, 2015 at 9:30am — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+